Stockscreener 앱 받기
0.6201
20.51%
-0.16
시간 외 거래:
.61
-0.0101
-1.63%
Conduit Pharmaceuticals Inc 주식(CDT)의 최신 뉴스
Conduit Pharmaceuticals Announces Leadership Changes - MarketScreener
Conduit Pharmaceuticals Inc. Announces Chief Executive Officer Changes, Effective April 16, 2025 - MarketScreener
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For Vtama® - MarketScreener
Strategic Patent Filing Could Transform VTAMA's $233B Market Potential - Stock Titan
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program - The Manila Times
Conduit Pharma Signals Stock Undervalued: Announces $1M Buyback as Phase II Trials Near - Stock Titan
Conduit Pharmaceuticals expands partnership with Sarborg - MSN
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization - The Manila Times
Machine Learning Deal: How Conduit Pharma Plans to Revolutionize Drug Development - Stock Titan
Analyzing Conduit Pharmaceuticals (CDT) and Its Competitors - Defense World
Conduit Pharmaceuticals meets Nasdaq listing standards By Investing.com - Investing.com Australia
Conduit Pharmaceuticals meets Nasdaq listing standards - Investing.com
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - The Manila Times
Major Patent Win: Conduit's Autoimmune Drug Gets 20-Year Market Protection - Stock Titan
Conduit Pharmaceuticals Inc. (CDT) reports earnings - Quartz
CONDUIT PHARMACEUTICALS INC. SEC 10-K Report - TradingView
CONDUIT PHARMACEUTICALS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Conduit Pharma Highlights Progress In Lupus Studies, Phase II Trial For AZD1656 - Nasdaq
Conduit Pharmaceuticals progresses in autoimmune drug studies By Investing.com - Investing.com Australia
Conduit Pharmaceuticals progresses in autoimmune drug studies - Investing.com
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904 - The Manila Times
Conduit Pharmaceuticals Reports Significant R&D Advancements in Lupus Studies and Pipeline Development - Nasdaq
Conduit's Triple-Drug Pipeline Shows Promise for Lupus TreatmentMajor R&D Breakthrough - StockTitan
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Update - The AM Reporter
Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now? - Insider Monkey
Conduit Pharmaceuticals Gets Nasdaq Extension, Plans Capital Market Transfer - MarketScreener
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel - The Manila Times
Conduit Pharmaceuticals secures Nasdaq extension - Investing.com
Conduit Pharmaceuticals Secures Extension for Nasdaq Compliance Following Bid Price Regaining - Nasdaq
Can Conduit Pharmaceuticals Keep Its Nasdaq Listing? Critical Deadlines Ahead - StockTitan
Conduit Pharmaceuticals secures Nasdaq extension By Investing.com - Investing.com Australia
Conduit Pharmaceuticals Inc (NASDAQ: CDT) Is Down -83.09% So Far This Year: What Will Happen Next? - Stocks Register
Taking a look at what insiders are doing to gauge the Conduit Pharmaceuticals Inc (CDT)’s direction - Knox Daily
Conduit Pharmaceuticals Advances Phase II AI Collaboration With Sarborg To Enhance Drug Development - Nasdaq
Conduit Progresses Phase II of its AI Initiative with Sarborg - The Manila Times
How Conduit's New AI System Could Revolutionize Drug Development Decision-Making - StockTitan
Conduit Pharmaceuticals acts to regain Nasdaq compliance By Investing.com - Investing.com South Africa
Conduit Pharmaceuticals acts to regain Nasdaq compliance - Investing.com India
Conduit Pharmaceuticals Files For Offering Of Up To $17.8 Million Of Shares Of Common StockSEC Filing - Marketscreener.com
Conduit Pharmaceuticals Awaits Nasdaq Decision on Compliance - TipRanks
Understanding the Risks of Investing in Conduit Pharmaceuticals Inc (CDT) - Knox Daily
Conduit Pharmaceuticals to execute 1-for-100 reverse stock split - MSN
Conduit Pharmaceuticals enacts reverse stock split to meet Nasdaq standards - MSN
Conduit Pharmaceuticals, Charles River Laboratories Partner to Evaluate Potential Lupus Treatment - Marketscreener.com
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model - The Manila Times
Major Lupus Breakthrough? Conduit Teams Up with Charles River for Game-Changing Treatment Study - StockTitan
Weekly TechBio News 🤹 - substack.com
Conduit Pharmaceuticals announces debt repayment and partial conversion of senior secured note - MSN
Small Cap Stocks To Watch NowFebruary 09th - MarketBeat
Promising Small Cap Stocks To Keep An Eye OnFebruary 07th - MarketBeat
Conduit Pharmaceuticals settles debt, converts senior note - MSN
2.51%
자본화:
|
볼륨(24시간):